Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Drug Safety Enhancement Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE via SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
2012 · fourth_quarter · Q4
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. Pub. Law No. 112-240, American Taxpayer Relief Act of 2012, primarily matters related to funding for the National Breast and Cervical Cancer Early Detection Program and the National Institutes of Health.
Source: Senate LDA
Drug Safety Enhancement Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.3070/S.1599, Department of Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing an order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Support of draft congressional resolution for reauthorization of the Prescription Drug User Fee Act (PDUFA), primarily matters related to drug shortages, drug approval and patient access.
Drug Safety Enhancement Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. H.R. 6157, Patient Centered Quality Care for Life Act of 2012
Drug Safety Enhancement Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. Pub. Law No. 112-240, American Taxpayer Relief Act of 2012, primarily matters related to funding for the National Breast and Cervical Cancer Early Detection Program and the National Institutes of Health.
Preserving Access to Life-Saving Medications Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. Pub. Law No. 112-240, American Taxpayer Relief Act of 2012, primarily matters related to funding for the National Breast and Cervical Cancer Early Detection Program and the National Institutes of Health.
Preserving Access to Life-Saving Medications Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.3070/S.1599, Department of Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing an order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Support of draft congressional resolution for reauthorization of the Prescription Drug User Fee Act (PDUFA), primarily matters related to drug shortages, drug approval and patient access.
Preserving Access to Life-Saving Medications Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. H.R. 6157, Patient Centered Quality Care for Life Act of 2012
Preserving Access to Life-Saving Medications Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012.
Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012.
Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. H.R. 6157, Patient Centered Quality Care for Life Act of 2012
Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. Pub. Law No. 112-240, American Taxpayer Relief Act of 2012, primarily matters related to funding for the National Breast and Cervical Cancer Early Detection Program and the National Institutes of Health.
Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.3070/S.1599, Department of Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing an order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Support of draft congressional resolution for reauthorization of the Prescription Drug User Fee Act (PDUFA), primarily matters related to drug shortages, drug approval and patient access.
Cancer Drug Coverage Parity Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. H.R. 6157, Patient Centered Quality Care for Life Act of 2012
Cancer Drug Coverage Parity Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. Pub. Law No. 112-240, American Taxpayer Relief Act of 2012, primarily matters related to funding for the National Breast and Cervical Cancer Early Detection Program and the National Institutes of Health.
Cancer Drug Coverage Parity Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012.
Cancer Drug Coverage Parity Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.3070/S.1599, Department of Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing an order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Support of draft congressional resolution for reauthorization of the Prescription Drug User Fee Act (PDUFA), primarily matters related to drug shortages, drug approval and patient access.
Accelerating the End of Breast Cancer Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012.
Accelerating the End of Breast Cancer Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. H.R. 6157, Patient Centered Quality Care for Life Act of 2012
Accelerating the End of Breast Cancer Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.3070/S.1599, Department of Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing an order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Support of draft congressional resolution for reauthorization of the Prescription Drug User Fee Act (PDUFA), primarily matters related to drug shortages, drug approval and patient access.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.3070/S.1599, Department of Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing an order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Support of draft congressional resolution for reauthorization of the Prescription Drug User Fee Act (PDUFA), primarily matters related to drug shortages, drug approval and patient access.
Breast Density and Mammography Reporting Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. H.R. 6157, Patient Centered Quality Care for Life Act of 2012
Breast Density and Mammography Reporting Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012.
Breast Density and Mammography Reporting Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.3070/S.1599, Department of Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing an order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Support of draft congressional resolution for reauthorization of the Prescription Drug User Fee Act (PDUFA), primarily matters related to drug shortages, drug approval and patient access.
Breast Density and Mammography Reporting Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. Pub. Law No. 112-240, American Taxpayer Relief Act of 2012, primarily matters related to funding for the National Breast and Cervical Cancer Early Detection Program and the National Institutes of Health.
Research Works Act
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012.
Research Works Act
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.3070/S.1599, Department of Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing an order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Support of draft congressional resolution for reauthorization of the Prescription Drug User Fee Act (PDUFA), primarily matters related to drug shortages, drug approval and patient access.
Research Works Act
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. H.R. 6157, Patient Centered Quality Care for Life Act of 2012
Research Works Act
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. Pub. Law No. 112-240, American Taxpayer Relief Act of 2012, primarily matters related to funding for the National Breast and Cervical Cancer Early Detection Program and the National Institutes of Health.
Comprehensive Cancer Care Improvement Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012.
Comprehensive Cancer Care Improvement Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. Pub. Law No. 112-240, American Taxpayer Relief Act of 2012, primarily matters related to funding for the National Breast and Cervical Cancer Early Detection Program and the National Institutes of Health.
Comprehensive Cancer Care Improvement Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.3070/S.1599, Department of Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing an order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Support of draft congressional resolution for reauthorization of the Prescription Drug User Fee Act (PDUFA), primarily matters related to drug shortages, drug approval and patient access.
Comprehensive Cancer Care Improvement Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. H.R. 6157, Patient Centered Quality Care for Life Act of 2012
Drug Shortage Prevention Act of 2012
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. Pub. Law No. 112-240, American Taxpayer Relief Act of 2012, primarily matters related to funding for the National Breast and Cervical Cancer Early Detection Program and the National Institutes of Health.
Drug Shortage Prevention Act of 2012
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012.
Drug Shortage Prevention Act of 2012
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.3070/S.1599, Department of Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing an order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Support of draft congressional resolution for reauthorization of the Prescription Drug User Fee Act (PDUFA), primarily matters related to drug shortages, drug approval and patient access.
Drug Shortage Prevention Act of 2012
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. H.R. 6157, Patient Centered Quality Care for Life Act of 2012
Patients' Access to Treatments Act of 2012
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. H.R. 6157, Patient Centered Quality Care for Life Act of 2012
Patients' Access to Treatments Act of 2012
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. Pub. Law No. 112-240, American Taxpayer Relief Act of 2012, primarily matters related to funding for the National Breast and Cervical Cancer Early Detection Program and the National Institutes of Health.
Patients' Access to Treatments Act of 2012
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012.
Breast Cancer Patient Education Act of 2012
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. Pub. Law No. 112-240, American Taxpayer Relief Act of 2012, primarily matters related to funding for the National Breast and Cervical Cancer Early Detection Program and the National Institutes of Health.
Breast Cancer Patient Education Act of 2012
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012.
Breast Cancer Patient Education Act of 2012
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. H.R. 6157, Patient Centered Quality Care for Life Act of 2012
Patient Centered Quality Care for Life Act
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. H.R. 6157, Patient Centered Quality Care for Life Act of 2012
Breast Cancer Patient Protection Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions, provisions on breast health education and postal provision. (Continued on Addendum) H.R.3070/S.1599, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and breast cancer programs. H.R.466/S. 384, Breast Cancer Research Stamp Reauthorization Act. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to cancer treatments. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3613, Part D Beneficiary Appeals Fairness Act, primarily matters related to specialty tiers of prescription drugs. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.111, Breast Cancer Patient Protection Act of 2011.
Breast Cancer Patient Protection Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education. H.R.3070/S.1599, Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2012, and for other purposes, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219/Senate companion bill, Department of Defense Appropriations Act, related to appropriations for Congressional Directed Medical Research Programs. H.R.466/S. 384, Breast Cancer Research Stamp Reauthorization Act. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to cancer treatments. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and breast cancer programs. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.111, Breast Cancer Patient Protection Act of 2011
Preserving Access to Life-Saving Medications Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions, provisions on breast health education and postal provision. (Continued on Addendum) H.R.3070/S.1599, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and breast cancer programs. H.R.466/S. 384, Breast Cancer Research Stamp Reauthorization Act. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to cancer treatments. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3613, Part D Beneficiary Appeals Fairness Act, primarily matters related to specialty tiers of prescription drugs. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.111, Breast Cancer Patient Protection Act of 2011.
Preserving Access to Life-Saving Medications Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education. H.R.3070/S.1599, Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2012, and for other purposes, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219/Senate companion bill, Department of Defense Appropriations Act, related to appropriations for Congressional Directed Medical Research Programs. H.R.466/S. 384, Breast Cancer Research Stamp Reauthorization Act. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to cancer treatments. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and breast cancer programs. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.111, Breast Cancer Patient Protection Act of 2011
Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education. H.R.3070/S.1599, Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2012, and for other purposes, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219/Senate companion bill, Department of Defense Appropriations Act, related to appropriations for Congressional Directed Medical Research Programs. H.R.466/S. 384, Breast Cancer Research Stamp Reauthorization Act. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to cancer treatments. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and breast cancer programs. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.111, Breast Cancer Patient Protection Act of 2011
Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions, provisions on breast health education and postal provision. (Continued on Addendum) H.R.3070/S.1599, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and breast cancer programs. H.R.466/S. 384, Breast Cancer Research Stamp Reauthorization Act. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to cancer treatments. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3613, Part D Beneficiary Appeals Fairness Act, primarily matters related to specialty tiers of prescription drugs. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.111, Breast Cancer Patient Protection Act of 2011.
Cancer Drug Coverage Parity Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions, provisions on breast health education and postal provision. (Continued on Addendum) H.R.3070/S.1599, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and breast cancer programs. H.R.466/S. 384, Breast Cancer Research Stamp Reauthorization Act. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to cancer treatments. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3613, Part D Beneficiary Appeals Fairness Act, primarily matters related to specialty tiers of prescription drugs. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.111, Breast Cancer Patient Protection Act of 2011.
Cancer Drug Coverage Parity Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education. H.R.3070/S.1599, Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2012, and for other purposes, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219/Senate companion bill, Department of Defense Appropriations Act, related to appropriations for Congressional Directed Medical Research Programs. H.R.466/S. 384, Breast Cancer Research Stamp Reauthorization Act. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to cancer treatments. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and breast cancer programs. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.111, Breast Cancer Patient Protection Act of 2011
Accelerating the End of Breast Cancer Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions, provisions on breast health education and postal provision. (Continued on Addendum) H.R.3070/S.1599, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and breast cancer programs. H.R.466/S. 384, Breast Cancer Research Stamp Reauthorization Act. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to cancer treatments. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3613, Part D Beneficiary Appeals Fairness Act, primarily matters related to specialty tiers of prescription drugs. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.111, Breast Cancer Patient Protection Act of 2011.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions, provisions on breast health education and postal provision. (Continued on Addendum) H.R.3070/S.1599, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and breast cancer programs. H.R.466/S. 384, Breast Cancer Research Stamp Reauthorization Act. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to cancer treatments. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3613, Part D Beneficiary Appeals Fairness Act, primarily matters related to specialty tiers of prescription drugs. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.111, Breast Cancer Patient Protection Act of 2011.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education. H.R.3070/S.1599, Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2012, and for other purposes, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219/Senate companion bill, Department of Defense Appropriations Act, related to appropriations for Congressional Directed Medical Research Programs. H.R.466/S. 384, Breast Cancer Research Stamp Reauthorization Act. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to cancer treatments. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and breast cancer programs. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.111, Breast Cancer Patient Protection Act of 2011
Breast Density and Mammography Reporting Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions, provisions on breast health education and postal provision. (Continued on Addendum) H.R.3070/S.1599, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and breast cancer programs. H.R.466/S. 384, Breast Cancer Research Stamp Reauthorization Act. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to cancer treatments. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3613, Part D Beneficiary Appeals Fairness Act, primarily matters related to specialty tiers of prescription drugs. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.111, Breast Cancer Patient Protection Act of 2011.
Part D Beneficiary Appeals Fairness Act
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions, provisions on breast health education and postal provision. (Continued on Addendum) H.R.3070/S.1599, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and breast cancer programs. H.R.466/S. 384, Breast Cancer Research Stamp Reauthorization Act. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to cancer treatments. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3613, Part D Beneficiary Appeals Fairness Act, primarily matters related to specialty tiers of prescription drugs. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.111, Breast Cancer Patient Protection Act of 2011.
Comprehensive Cancer Care Improvement Act of 2011
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions, provisions on breast health education and postal provision. (Continued on Addendum) H.R.3070/S.1599, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and breast cancer programs. H.R.466/S. 384, Breast Cancer Research Stamp Reauthorization Act. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to cancer treatments. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3613, Part D Beneficiary Appeals Fairness Act, primarily matters related to specialty tiers of prescription drugs. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.111, Breast Cancer Patient Protection Act of 2011.
To amend title 39, United States Code, to extend the authority of the United States Postal Service to issue a semipostal to raise funds for breast cancer research.
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education. H.R.3070/S.1599, Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2012, and for other purposes, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219/Senate companion bill, Department of Defense Appropriations Act, related to appropriations for Congressional Directed Medical Research Programs. H.R.466/S. 384, Breast Cancer Research Stamp Reauthorization Act. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to cancer treatments. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and breast cancer programs. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.111, Breast Cancer Patient Protection Act of 2011
To amend title 39, United States Code, to extend the authority of the United States Postal Service to issue a semipostal to raise funds for breast cancer research.
Client: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE · Firm: SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions, provisions on breast health education and postal provision. (Continued on Addendum) H.R.3070/S.1599, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and breast cancer programs. H.R.466/S. 384, Breast Cancer Research Stamp Reauthorization Act. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to cancer treatments. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3613, Part D Beneficiary Appeals Fairness Act, primarily matters related to specialty tiers of prescription drugs. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.111, Breast Cancer Patient Protection Act of 2011.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE via SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
2012 · third_quarter · Q3
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012. H.R. 6157, Patient Centered Quality Care for Life Act of 2012
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE via SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
2012 · second_quarter · Q2
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access. H.R. 4209, Patients' Access to Treatments Act of 2012. H.R. 5937, Breast Cancer Patient Education Act of 2012.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE via SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
2012 · first_quarter · Q1
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.3070/S.1599, Department of Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and CDC cancer prevention and control programs. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages. H.R. 3839, Drug Shortage Prevention Act of 2012. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain. H.R.3699, Research Works Act, primarily matters related to opposing an order to protect the NIH Public Access Policy. S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions. S.2236, Advancing Breakthrough Therapies for Patients Act of 2012. Support of draft congressional resolution for reauthorization of the Prescription Drug User Fee Act (PDUFA), primarily matters related to drug shortages, drug approval and patient access.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE via SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
2011 · fourth_quarter · Q4
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions, provisions on breast health education and postal provision. (Continued on Addendum) H.R.3070/S.1599, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and breast cancer programs. H.R.466/S. 384, Breast Cancer Research Stamp Reauthorization Act. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to cancer treatments. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. H.R.3613, Part D Beneficiary Appeals Fairness Act, primarily matters related to specialty tiers of prescription drugs. H.R.3102, Breast Density and Mammography Reporting Act of 2011. H.R.3067, Accelerating the End of Breast Cancer Act of 2011. H.R.3705, Comprehensive Cancer Care Improvement Act of 2011. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.111, Breast Cancer Patient Protection Act of 2011.
Filing targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE via SUSAN G. KOMEN FOR THE CURE ADVOCACY ALLIANCE
2011 · third_quarter · Q3
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education. H.R.3070/S.1599, Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2012, and for other purposes, primarily matters related to appropriations for cancer research and cancer screening programs. H.R.2219/Senate companion bill, Department of Defense Appropriations Act, related to appropriations for Congressional Directed Medical Research Programs. H.R.466/S. 384, Breast Cancer Research Stamp Reauthorization Act. H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to cancer treatments. H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011. Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and breast cancer programs. H.R.2746, Cancer Drug Coverage Parity Act of 2011. H.R.111, Breast Cancer Patient Protection Act of 2011
Filing targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE